###begin article-title 0
Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau
###end article-title 0
###begin p 1
Conceived and designed the experiments: SM DH AB. Performed the experiments: SM TG BS BG IV RC PA KM FJ DH CM QL KL. Analyzed the data: SM TG AH BS BG IV RC PA KM FJ DH CM QL KL AB. Contributed reagents/materials/analysis tools: SM BG CM AB. Wrote the paper: SM TG AH BG PA KM AB.
###end p 1
###begin p 2
###xml 737 741 736 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 1260 1264 1259 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 373 377 <span type="species:ncbi:10090">Mice</span>
###xml 577 581 <span type="species:ncbi:10090">mice</span>
###xml 747 751 <span type="species:ncbi:10090">mice</span>
###xml 979 983 <span type="species:ncbi:10090">mice</span>
###xml 1215 1220 <span type="species:ncbi:10090">mouse</span>
###xml 1274 1278 <span type="species:ncbi:10090">mice</span>
Age-related neurodegenerative disease has been mechanistically linked with mitochondrial dysfunction via damage from reactive oxygen species produced within the cell. We determined whether increased mitochondrial oxidative stress could modulate or regulate two of the key neurochemical hallmarks of Alzheimer's disease (AD): tau phosphorylation, and ss-amyloid deposition. Mice lacking superoxide dismutase 2 (SOD2) die within the first week of life, and develop a complex heterogeneous phenotype arising from mitochondrial dysfunction and oxidative stress. Treatment of these mice with catalytic antioxidants increases their lifespan and rescues the peripheral phenotypes, while uncovering central nervous system pathology. We examined sod2 null mice differentially treated with high and low doses of a catalytic antioxidant and observed striking elevations in the levels of tau phosphorylation (at Ser-396 and other phospho-epitopes of tau) in the low-dose antioxidant treated mice at AD-associated residues. This hyperphosphorylation of tau was prevented with an increased dose of the antioxidant, previously reported to be sufficient to prevent neuropathology. We then genetically combined a well-characterized mouse model of AD (Tg2576) with heterozygous sod2 knockout mice to study the interactions between mitochondrial oxidative stress and cerebral Ass load. We found that mitochondrial SOD2 deficiency exacerbates amyloid burden and significantly reduces metal levels in the brain, while increasing levels of Ser-396 phosphorylated tau. These findings mechanistically link mitochondrial oxidative stress with the pathological features of AD.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 186 189 186 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Strassburger1">[1]</xref>
###xml 190 193 190 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov2">[3]</xref>
###xml 364 368 364 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 389 392 389 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Strassburger1">[1]</xref>
###xml 394 397 394 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Qi1">[4]</xref>
###xml 447 450 447 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Li1">[5]</xref>
###xml 452 455 452 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Huang1">[6]</xref>
###xml 522 525 522 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Li1">[5]</xref>
###xml 527 530 527 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Huang1">[6]</xref>
###xml 547 550 547 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Li1">[5]</xref>
###xml 552 555 552 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Huang1">[6]</xref>
###xml 574 577 574 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Friedman1">[7]</xref>
###xml 579 582 579 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Friedman2">[8]</xref>
###xml 593 596 593 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Huang1">[6]</xref>
###xml 628 631 628 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-VanRemmen1">[9]</xref>
###xml 653 657 653 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Samper1">[10]</xref>
###xml 693 697 693 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov3">[11]</xref>
###xml 699 703 699 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Hinerfeld1">[12]</xref>
###xml 731 734 731 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov2">[3]</xref>
###xml 753 756 753 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Qi1">[4]</xref>
###xml 777 780 777 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov2">[3]</xref>
###xml 782 785 782 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Huang1">[6]</xref>
###xml 808 812 808 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Hinerfeld1">[12]</xref>
###xml 935 939 935 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 964 967 964 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov1">[2]</xref>
###xml 969 972 969 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov2">[3]</xref>
###xml 974 978 974 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Ali1">[13]</xref>
###xml 1118 1121 1118 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov1">[2]</xref>
###xml 1123 1126 1123 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov2">[3]</xref>
###xml 1144 1147 1144 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Friedman1">[7]</xref>
###xml 1319 1323 1319 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Hinerfeld1">[12]</xref>
###xml 1325 1329 1325 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Golden1">[14]</xref>
###xml 320 324 <span type="species:ncbi:10090">Mice</span>
###xml 952 957 <span type="species:ncbi:10090">mouse</span>
Mitochondria are a main source of potentially pathogenic reactive oxygen species (ROS) such as superoxide, particularly in highly metabolically active organs such as the brain and heart [1]-[3]. The chief defense against superoxide produced during the course of respiration is mitochondrial superoxide dismutase (SOD2). Mice have been genetically modified to lack sod2 in specific tissues [1], [4], or systemically in multiple genetic backgrounds [5], [6]. The resulting phenotypes include neonatal or embryonic lethality [5], [6], cardiomyopathy [5], [6], hemolytic anemia [7], [8], seizures [6], increased incidence of cancer [9], genomic instability [10], mitochondrial biochemical defects [11], [12], spongiform encephalopathy [3], optic neuropathy [4], movement disorders [3], [6] and neurodegeneration [12]. These phenotypes arise due to endogenous oxidative stress and several antioxidant interventions have been applied to the sod2 nullizygous mouse model [2], [3], [13]. Some of these interventions have striking efficacy in preventing cardiomyopathy, extending lifespan, preventing spongiform encephalopathy [2], [3], reducing anemia [7], increasing mitochondrial enzyme activity, reducing neurodegeneration and attenuating gene expression characteristic of mitochondrially mediated spongiform encephalopathy [12], [14].
###end p 4
###begin p 5
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Barnham1">[15]</xref>
###xml 256 260 256 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Iqbal1">[16]</xref>
###xml 318 322 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Schonheit1">[17]</xref>
###xml 424 425 421 422 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 426 427 423 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 427 431 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Huang2">[18]</xref>
###xml 433 437 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Opazo1">[19]</xref>
###xml 651 655 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Barnham1">[15]</xref>
###xml 803 807 799 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Hsiao1">[20]</xref>
###xml 808 812 804 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Richardson1">[22]</xref>
###xml 933 937 929 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Oddo1">[23]</xref>
###xml 1273 1277 1268 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Oddo2">[24]</xref>
###xml 1470 1474 1465 1469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Santacruz1">[25]</xref>
###xml 1575 1579 1570 1574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Esposito1">[26]</xref>
###xml 1581 1585 1576 1580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Li2">[27]</xref>
###xml 1658 1662 1653 1657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 1795 1799 1790 1794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Esposito1">[26]</xref>
###xml 842 857 <span type="species:ncbi:10090">transgenic mice</span>
###xml 945 949 <span type="species:ncbi:10090">mice</span>
###xml 1259 1264 <span type="species:ncbi:9606">human</span>
###xml 1294 1309 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1383 1387 <span type="species:ncbi:10090">mice</span>
###xml 1476 1480 <span type="species:ncbi:10090">Mice</span>
###xml 1587 1591 <span type="species:ncbi:10090">Mice</span>
###xml 1636 1640 <span type="species:ncbi:10090">mice</span>
###xml 1688 1692 <span type="species:ncbi:10090">mice</span>
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is associated with oxidative stress [15] and the accumulation of two characteristic pathologies, neurofibrillary tangles, composed primarily of hyperphosphorylated aggregates of tau [16], and amyloid plaques, largely composed of aggregated Ass [17]. Ass binds copper and zinc selectively in AD tissue, and Ass:Cu complexes are a catalytic source of H2O2[18], [19]. The molecular mechanism that results in an aggregation of Ass with increasing age in the brain is still uncertain, but abnormal interactions with biometals (principally copper and zinc) may play a prominent role [15]. To aid in the development of therapeutic strategies for AD, a number of animal models have been developed which recapitulate the plaque pathology [20]-[22]. However, only recently have transgenic mice been developed which model the two key neuropathologies associated with AD [23]. These mice progressively develop both amyloid and tau pathology, which are both associated with synaptic dysfunction. Of note in this genetic model, Ass deposition preceded the development of phosphorylated tau, and the distribution of phospho-tau closely recapitulated the distribution of tangles that characterize the human disease [24]. More recently, transgenic mice were developed which overexpressed mutant tau by 7-13 fold, resulting in mice that develop a tauopathy associated with neurodegeneration and impaired cognition [25]. Mice that model mitochondrial dysfunction and Alzheimers disease have only recently been developed [26], [27]. Mice overexpressing mutant APP were crossed with mice heterozygous for sod2, resulting in strains of mice with acceleration of amyloid accumulation, in addition to increasing behavioral defects in one strain [26].
###end p 5
###begin p 6
###xml 327 331 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Hsiao1">[20]</xref>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Oddo1">[23]</xref>
###xml 339 343 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Santacruz1">[25]</xref>
###xml 345 349 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-vanLeuven1">[28]</xref>
###xml 351 355 351 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Holcomb1">[29]</xref>
###xml 608 612 608 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 881 885 881 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 510 515 <span type="species:ncbi:9606">human</span>
###xml 593 597 <span type="species:ncbi:10090">mice</span>
###xml 823 827 <span type="species:ncbi:10090">mice</span>
A key question that remains unresolved in all currently available animal models of AD, is how well do they model AD where there are no mutations in either APP or tau? The majority of current animal models of AD are based on the overexpression of mutant forms of genes associated with AD linked to aggressive familial mutations [20], [23], [25], [28], [29]. Therefore, a significant need exists for the development of animal models of the neuropathology of AD, which are not based upon overexpression of mutant human proteins. Here we describe a novel model for AD neuropathology, showing that mice that lack sod2 express AD-like hyperphosphorylation of tau, the protein component of neurofibrillary tangles. We show that this hyperphosphorylation of tau is attributable to mitochondrial oxidative stress. We also show that mice that are both transgenic for APP, and hemizygous for sod2, incur a higher level of tau phosphorylation, higher amyloid burden and decreased copper, zinc and manganese levels, consistent with a synergistic interaction between APP and mitochondrial oxidative stress in contributing to AD-like neocortical pathology.
###end p 6
###begin title 7
Methods
###end title 7
###begin title 8
Animal husbandry
###end title 8
###begin p 9
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sod2</italic>
###xml 242 245 242 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov1">[2]</xref>
###xml 247 250 247 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov2">[3]</xref>
###xml 360 364 360 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 437 441 <span type="species:ncbi:10090">Mice</span>
Sod2 nullizgyous mice of both sexes were genotyped between 2 and 3 days of age, and injected intraperitoneally with EUK189 at either 1 mg/kg (low dose) or 30 mg/kg (high dose) daily from 3 days of age until sacrifice, as previously described [2], [3]. EUK189 was purchased from Dalton Chemical Laboratories, Inc (Toronto, Canada). Wild type animals as well as sod2 nullizygous mice were treated to control for compound specific effects. Mice were killed at 18-21 days of age and cortex harvested immediately for use in histological or biochemical studies.
###end p 9
###begin p 10
###xml 7 11 7 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 139 143 139 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 208 212 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Hsiao1">[20]</xref>
###xml 270 274 270 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 335 339 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Hsiao1">[20]</xref>
###xml 348 352 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 398 402 398 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 756 760 756 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Callahan1">[30]</xref>
###xml 19 23 <span type="species:ncbi:10090">mice</span>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 275 279 <span type="species:ncbi:10090">mice</span>
###xml 353 357 <span type="species:ncbi:10090">mice</span>
###xml 366 370 <span type="species:ncbi:10090">mice</span>
###xml 697 701 <span type="species:ncbi:10090">mice</span>
Tg2576:sod2 hybrid mice were created by crossing C57BL/6 sod2 null mice (a kind gift of C.J. Epstein) to SJL mice to create F1 C57BL/6:SJL sod2 heterozygotes. These mice were then crossed to APP mice (Tg2576 [20], on an identical genetic background), to generate Tg2576:sod2 mice, which were maintained and bred as previously reported [20]. Tg2576:sod2 mice, Tg2576 mice, and C57BL/6:SJL F1 hybrid sod2 heterozygotes were maintained under barrier conditions until 497-527 days of age, when they were killed and neocortices were either harvested and frozen for biochemical analysis, or fixed in neutral buffered formalin for histological processing using standard protocols. We chose female Tg2576 mice to study because they have more robust plaque changes [30]. All animal procedures were carried out under approved IACUC animal protocols at the Buck Institute, which is AAALAC accredited.
###end p 10
###begin title 11
Immunohistochemistry
###end title 11
###begin p 12
###xml 1599 1603 1589 1593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Kobayashi1">[31]</xref>
###xml 522 528 <span type="species:ncbi:9793">donkey</span>
###xml 622 628 <span type="species:ncbi:9986">rabbit</span>
###xml 991 997 <span type="species:ncbi:9793">donkey</span>
###xml 1003 1009 <span type="species:ncbi:9986">rabbit</span>
Parrafin embedded brain tissue was cut at a thickness of 8 microm, and tissue sections were de-paraffinised with xylene and re-hydrated through a stepwise series of ethanol solutions (100%, 95%, 70%). Non-specific background was reduced by a 5 minute pre-incubation in 0.5X PBS, in 10% methanol plus 3% hydrogen peroxide for 20 to 30 minutes. Antigen retrieval was routinely used with a commercially available kit (Antigen Unmasking Solution, Vector Lab., Burlingame CA). All slides were blocked (0.01X PBS, 5% v/v normal donkey serum, 0.1% Triton X-100) for 2 hours at room temperature, after which the primary antibody (rabbit anti-phospho-Ser 396 tau antibody, BioSource, Camarillo, CA) was added and left over 2 nights at 4degreesC. To ensure specificity of signal, a specific phospho-blocking peptide for phospho Ser-396 was used on adjacent serial sections (BioSource), which completely blocked the signal from the primary antibody. The secondary antibody (1:500, Biotin-SP-conjugated donkey anti-rabbit IgG, Jackson ImmunoResearch Lab, West Grove, PA) was incubated for one hour at room temperature and the resulting signal was visualized using the Vectastain ABC kit and VectaDAB kit (Vector Laboratories, Burlingame, CA) according to the manufacturer's instructions. All slides were counterstained in Mayer's Haematoxylin for 30 seconds, and then dehydrated before the application of cover-slips, and subsequent photography using a digital camera (AxioVision v3.1, Carl Zeiss Vision). Silver staining for detection of possible neurofibrillary tangles, was performed as previously described [31], with the following modifications: immersion in the alkaline solution was 10 seconds, and the physical developer components for 25degreesC (10 mL solution A+5 mL solution B+5 mL solution C) were used immediately after mixing. Sections were developed in this solution until they had turned pale to mid-grey (approximately 20 to 30 minutes).
###end p 12
###begin p 13
###xml 1297 1298 1288 1289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
For evaluating amyloid load, we cut 7 microm coronal sections from formalin-fixed brain tissue. The sections were treated with 80% formic acid for antigen retrieval before probing with monoclonal antibody 1E8 that recognizes an epitope between residues 18 and 22 of Abeta (Glaxo SmithKline, UK). All sections were imaged on a Northern Light Illuminator (Imaging Research Inc, Ontario, Canada) using a Spot RT-KE 2MP digital camera (Diagnostic Instruments, MI, USA) equipped with a Nikkon 55 mm lens and 56 mm extension tube set. Each image was analyzed using ImagePro Plus 5.1 (Media Cybernetics, MD, USA). For each image an "area of interest" (AOI) line was drawn around the margins of the brain occupied by the hippocampus and cortex. The number of ss-amyloid-positive structures present in each section were then quantitated using color selection to separate the plaques from background labeling. A filter was also utilized to only include structures that were greater than 10 pixels in size. This data was expressed as the total number of ss-amyloid-positive pixels in each section and was exported to Microsoft Excel for analysis. Based upon the known size of each AOI, all values were normalized to allow comparisons between sections of different surface area and were expressed as pixels/mm2. Average Ass load was assessed in the cortex and underlying grey matter taken from two sections from each animal and all counts represent Ass found only in plaques. In all cases, the investigator undertaking the analyses was blinded to animal genotype.
###end p 13
###begin title 14
Western blotting and quantitation of phospho tau
###end title 14
###begin p 15
###xml 1054 1058 1044 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Augustinack1">[32]</xref>
###xml 1105 1113 1095 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1</xref>
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
###xml 1260 1266 <span type="species:ncbi:9986">rabbit</span>
###xml 1435 1439 <span type="species:ncbi:9925">goat</span>
###xml 1445 1451 <span type="species:ncbi:9986">rabbit</span>
Protein was extracted from mouse cortex by homogenizing in tissue extraction buffer (50 mM Tris HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton, 0.1% SDS) containing mini complement protease inhibitors (Roche) at 4degreesC. Cellular debris was removed by centrifuging at 10,000 rpm in a bench top centrifuge for 5 minutes. Supernatant fractions were removed, and protein concentrations determined using a BCA protein assay kit (Pierce Biotechnology, Rockford, IL). Each sample was denatured in standard SDS/Page loading buffer and 2.5 microg of protein run on a NuPage 4-12% Bis Tris gels in MES buffer (Invitrogen, Carlsbad, CA). Proteins were transferred onto a Immuno-Blot PVDF membranes (Bio-Rad, Hercules, CA), according to the manufacturer's instructions. Blocking was carried in a standard 5% fat free milk solution in 1xTBS (0.05% Tween) for 1 hour at room temperature. Five anti-phospho-tau antibodies were employed which were directed against specific residues that had been previously identified as sites of hyper phosphorylation of tau in AD [32]; Thr-205, Ser-396, Ser-404, Ser-214, Thr-231 (Figure 1). Anti-phospho tau primary antibodies (Biosource, anti phospho-Thr 205, anti phospho-Ser 396, anti phospho-Ser 404, and anti phospho-Thr 214, all rabbit) (Chemicon, Temecula, CA) were typically used at a concentration of between 1:1000 to 1:10000, diluted in blocking buffer. The secondary antibody was an HRP-conjugated goat anti-rabbit (Pierce). Chemiluminescent detection was conducted with the ECL Plus western blotting detection system (Amersham Biosciences, Piscataway, NJ) and X-ray film according to manufacturer's instructions.
###end p 15
###begin p 16
A number of preliminary blots were run for each antibody to determine the optimal conditions for quantification of phosphorylated tau. In these preliminary studies, the amount of protein was varied per gel, or the concentration of primary antibody varied in order to estimate the linear range of quantifiable phospho-tau.
###end p 16
###begin p 17
###xml 395 408 395 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I(Geno&#8202;=&#8202;&#8722;/&#8722;)</italic>
###xml 670 674 670 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-White1">[33]</xref>
###xml 819 820 816 817 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 815 824 815 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;<sub>4</sub>&#8202;=&#8202;0</italic>
###xml 976 977 973 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 999 1007 996 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1</xref>
Because the amount of tau protein in the sample could potentially contribute to the amount of phosphorylation at specific residues, we normalized by the total amount of tau in each sample. Instead of using a normalized outcome (such as the ratio of residue/tau), we adjust for the amount of tau using a simple linear modeling approach. Specifically, for each residue we estimate the model:where I(Geno = -/-) is the indicator function ( = 1 if genotype is -/-, 0 otherwise, Tx is treatment). This model permits the testing and estimation of dose effects within genotype and similarly, genotypes within dose groups. The inference was derived using robust standard errors [33]. Note, in none of the models was the amount of total tau significantly associated with a specific outcome (i.e., the p-value of the test of beta4 = 0 was >0.05 for all residues). Comparison between specific groups using the above regression modeling after adjusting for total tau and their associated p-values are listed in Figure 1.
###end p 17
###begin title 18
Immunoprecipitation of phosphorylated tau
###end title 18
###begin p 19
###xml 410 414 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 533 537 513 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 335 340 <span type="species:ncbi:10090">mouse</span>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
###xml 541 545 <span type="species:ncbi:10090">mice</span>
Immunoprecipitation was carried out using the Seize(R) Primary Immunoprecipitation Kit from Pierce, according to the manufacturer's instructions. 100 microg of Tau-5 anti-tau antibody (BioSource) was coupled to the 200 microl of AminoLink(R) Plus Coupling Gel Protein as per the manufacturer's instructions. Brain extracts (1.2 mg per mouse, for a total of 6 mg in 750 microl) were pooled from five 18-day-old sod2 null mice that had been treated with a low dose of Euk189, or brain extracts (50 microl each) from nine female Tg2576:sod2+/- mice were pooled for a total of 1.8 mg in 450 microl. The pooled extracts were diluted to 5 ml with Binding Buffer, the 200 microl of antibody-coupled resin added, and the mixture rotated overnight at 4degreesC. Subsequent washes and elution were carried out as per the manufacturer's instructions. All bound tau protein was found to be eluted from the resin in the first 200 microl elution fraction.
###end p 19
###begin title 20
Proteolytic digestion of immunoprecipitated tau
###end title 20
###begin p 21
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 332 333 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 336 337 332 333 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
Phosphorylated tau protein was either immunoprecipitated from single mutant (sod2-/-) mouse brain tissue as described above and was directly processed following a manual in-solution digestion protocol. Approximately 0.3-0.4 microg of immunoprecipitated tau in elution buffer (100 mM glycine) was brought to pH 8.0 by adding 50 mM NH4HCO3 buffer (final total volume 60 microl). Subsequently, acetonitrile (ACN) was added (40% final concentration) to denature the protein. The protein was incubated at 60degreesC for 30 min with a 500-fold molar excess of reducing reagent DTT over the number of cysteine residues in tau, followed by an incubation at 37degreesC for 45 min after adding a 1100-fold molar exess of alkylating reagent iodoacetamide (DTT and iodoacetamide were both purchased from Sigma, St. Louis, MO). After dilution of the reaction mixture to 10% ACN, the sample was incubated with 40 ng sequencing grade trypsin (Promega, Madison, WI) at 37degreesC for 8 hours. The resulting tryptic peptides were acidified with formic acid, and then subjected to mass spectrometric analysis.
###end p 21
###begin title 22
Mass Spectrometric Analysis (ESI-MS/MS)
###end title 22
###begin p 23
###xml 418 419 401 402 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 713 714 692 693 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 783 784 762 763 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1372 1375 1349 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m/z</italic>
###xml 1595 1598 1572 1575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m/z</italic>
###xml 1617 1618 1594 1595 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 1628 1631 1605 1608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m/z</italic>
The proteolytic peptide mixtures were analyzed by reverse-phase nano-HPLC-MS/MS. Briefly, peptides were separated on an Ultimate nanocapillary HPLC system equipped with a PepMaptrade mark C18 nano-column (75 microm I.D. x15 cm) (Dionex, Sunnyvale, CA) and CapTrap Micro guard column (0.5 microl bed volume, Michrom, Auburn, CA). Peptide mixtures were loaded onto the guard column and washed with the loading solvent (H2O/0.05% formic acid, flow rate: 20 microl/min) for 5 min, then transferred onto the analytical C18-nanocapillary HPLC column and eluted at a flow rate of 300 nl/min using the following gradient: 2% B (from 0-5 min), and 2-70% B (from 5-55 min). Solvent A consisted of 0.05% formic acid in 98% H2O/2% ACN and solvent B consisted of 0.05% formic acid in 98% ACN/2% H2O. The column eluant was directly coupled to a 'QSTAR Pulsar i' quadrupole orthogonal TOF mass spectrometer (MDS Sciex, Concorde, Canada) equipped with a Protana/ProXeon nanospray ion source (ProXeon Biosystems, Odense, Denmark). The nanospray needle voltage was typically 2300 V in the HPLC-MS mode. Mass spectra (ESI-MS) and tandem mass spectra (ESI-MS/MS) were recorded in positive-ion mode with a resolution of 12,000-15,000 FWHM. For collision induced dissociation tandem mass spectrometry, the mass window for precursor ion selection of the quadrupole mass analyzer was set to +/-1 m/z. The precursor ions were fragmented in a collision cell using nitrogen as the collision gas. Spectra were calibrated in static nanospray mode using MS/MS fragment-ions of a renin peptide standard (His immonium-ion with m/z at 110.0713, and b8-ion with m/z at 1028.5312) providing a mass accuracy of </=50 ppm. Samples were run at least twice by HPLC-MS/MS. Mass lists were generated of potential phospho-peptides that were observed as ESI-MS fingerprints but were not selected by ESI-MS/MS in the first HPLC run. These mass lists were entered as inclusion lists to the Information Dependent Acquisition of the QSTAR instrument (to be selected for MS/MS) in subsequent runs.
###end p 23
###begin title 24
Database searches for protein identification and additional bioinformatics programs
###end title 24
###begin title 25
ESI-MS/MS data:
###end title 25
###begin p 26
###xml 312 316 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Perkins1">[34]</xref>
ESI-MS/MS data were submitted to our in-house search engine Mascot analyzing peptide sequence information from tandem mass spectra. The search engine Mascot uses a probability based 'Mowse Score' to evaluate data obtained from tandem mass spectra, e.g. for a score>37, protein matches are considered significant [34]. All acquired MS/MS spectra of phosphorylated peptides were interpreted and inspected "manually" and compared to the MS/MS spectra of their corresponding non-phosphorylated peptides.
###end p 26
###begin title 27
ESI-MS data:
###end title 27
###begin p 28
In order to obtain reliable peak lists from ESI-MS data that were generated during an LC-MS run, the programs Mascot Distiller (version 1.1.1) and Mascot Distiller MDRO Software Developers Kit (version 1.1.1) were purchased (Matrix Sciences, London, United Kingdom). An in-house developed java program named "MS-Assign" was used to interface with the Mascot Distiller software that was used for peak picking and to extract and compile ESI-MS peak lists from the LC-MS runs. Subsequently, ESI-PMF peak lists were submitted to our Mascot search engine or Protein Prospector.
###end p 28
###begin title 29
Evaluation of Ass load
###end title 29
###begin p 30
###xml 1373 1374 1329 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
We estimated Ass load using both immunohistochemistry (described above) and the DELFIA(R) Double Capture ELISA (Ritchie et al., 2003). Briefly, brain tissues (approximately0.2 g) were homogenized in PBS at a ratio of 1:10 (w/vol), and centrifuged at 100,000 g for 1 hr. The pellet was resuspended in the original volume and further solubilized with guanidine HCl to a final concentration of 5 M followed by centrifugation at 16,000 g for 20 minutes. To measure Ass40 or Ass42, the supernatants were diluted 1:10 with blocking buffer (0.25% casein or Superblock (Pierce) in phosphate-buffered saline with 0.025% Tween-20) before adding to the plate. For the detection of Ass40 or Ass42 in the 100,000 g soluble fraction, 50 microl of the soluble fractions were applied to the ELISA plates. Plates were coated with either G210 (for Abeta40) or G211 (for Abeta42) antibodies, which are specific for the C-terminus of Abeta, then blocked with 0.5% (w/v) casein/PBS or Superblock/PBS buffer (pH 7.4). After washing the plates, WO2-Biotin was added to the wells. The epitope for WO2 is within residues 5-8. Abeta40 and Abeta42 peptide standards and samples were assayed in triplicate, and incubated overnight at 4degreesC. The plates were washed, europium labelled streptavidin added, and then developed with enhancement solution. Analysis was carried out using the Wallac Victor2 1420 Multilabel Plate Reader (PerkinElmer, Melbourne, Australia) with excitation at 340 nm and emission at 613 nm.
###end p 30
###begin p 31
###xml 190 195 <span type="species:ncbi:9606">human</span>
###xml 226 231 <span type="species:ncbi:10090">mouse</span>
Levels of the amyloid precursor protein (APP), the parent molecule of Ass, were quantitated by Western blot using the antibody 22C11 (Boehringer), which detects both the transgene-expressed human APP as well as the endogenous mouse APP. Briefly, snap-frozen tissues were thawed and homogenized in PBS (pH 7.4, 2 ml) and centrifuged at 100,000 g for 30 minutes. The pellet was resuspended 1:1000 (w/v) in PBS and aliquots dissolved by extensive boiling in 8% SDS sample buffer containing 10% mercaptoethanol prior to separation on PAGE.
###end p 31
###begin p 32
###xml 78 79 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Statistical analysis was carried out between genotypes using a non-parametric t-test (two-sided) (PRISM, Graphpad, San Diego, CA).
###end p 32
###begin title 33
ICP-MS evaluation of metal content of soluble and insoluble amyloid fractions
###end title 33
###begin p 34
Cortical samples were sonicated in 1 ml of PBS, centrifuged at 100,000 g for 30 minutes 4degreesC. The supernatant was collected and the pellet was resuspended in 1 ml of PBS.
###end p 34
###begin p 35
###xml 186 190 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Maynard1">[35]</xref>
###xml 470 471 462 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
A 500 microl aliquot of each brain pellet suspension was lyophilised. Samples were assayed by inductive-coupled plasma mass spectrometry according to our previously published procedures [35]. Results are expressed as the average of the three triplicates in micrograms of metal per g of protein (microg/g). Note: The levels of cobalt and aluminium in the samples were below detectable levels. Statistical analysis was carried out between genotypes using a non-parametric t-test (two-sided).
###end p 35
###begin title 36
Results
###end title 36
###begin title 37
Mitochondrial oxidative stress causes hyperphosphorylation of tau
###end title 37
###begin p 38
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 284 287 284 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov1">[2]</xref>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Golden1">[14]</xref>
###xml 369 372 369 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov1">[2]</xref>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 528 531 528 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov1">[2]</xref>
###xml 556 560 556 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 838 841 838 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov1">[2]</xref>
###xml 843 847 843 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Golden1">[14]</xref>
###xml 898 902 898 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sod2</italic>
###xml 1055 1058 1055 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Li1">[5]</xref>
###xml 1060 1064 1060 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov3">[11]</xref>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 566 570 <span type="species:ncbi:10090">mice</span>
###xml 908 912 <span type="species:ncbi:10090">mice</span>
To test whether mitochondrial oxidative stress causes hyperphosphorylation of tau, we studied sod2 null mice that were treated with a catalytic antioxidant (EUK189). A low dose of EUK189 (1 mg/kg) rescues the peripheral phenotypes in these mice and extends the lifespan up to 3 weeks [2], while revealing a spongiform encephalopathy [14] and severe behavioral disorder [2]. This treatment response is concordant when sod2 null mice are treated with other closely related antioxidant regimens (EUK8, EUK134, analogues of EUK189, [2]). In contrast, treating sod2 null mice with a high dose of EUK189 (30 mg/kg) improves survival, behavioral abnormalities, and transcriptional responses associated with oxidative stress, in conjunction with increasing activities of mitochondrial enzymes that are sensitive to mitochondrial oxidative stress [2], [14], as well as preventing spongiform neuropathology. Sod2 null mice that are not treated with antioxidants die within the first week of life from peripheral organ failure without any observable brain pathology [5], [11]. Hence they are unsuitable to examine the effects of endogenous oxidative stress on the brain.
###end p 38
###begin p 39
###xml 516 520 516 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 595 598 595 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov1">[2]</xref>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 190 194 <span type="species:ncbi:10090">Mice</span>
###xml 415 419 <span type="species:ncbi:10090">mice</span>
###xml 526 530 <span type="species:ncbi:10090">mice</span>
By comparing the low and high dose antioxidant treated groups of mice, we were able to contrast the effects of mitochondrial oxidative stress on the potential phosphorylation status of tau. Mice were killed (N = 6-8 per treatment group), frontal cortices were harvested, and protein was extracted and western blotted for quantification of tau and phosphorylated tau. To control for drug specific effects, wild-type mice were also treated with either low or high dose of EUK189 for the same period of time. Untreated sod2 null mice on this genetic background do not survive long enough (<1 week, [2]) to serve as a negative control.
###end p 39
###begin p 40
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 87 96 87 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1A</xref>
###xml 125 126 125 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 224 228 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 383 392 383 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1A</xref>
###xml 677 681 677 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 525 529 <span type="species:ncbi:10090">mice</span>
###xml 687 691 <span type="species:ncbi:10090">mice</span>
First we asked whether lack of sod2 caused an increase in the abundance of tau itself (Figure 1A). Two tailed non-parametric t-tests were carried out to determine differential levels of total tau in frontal cortices between sod2 null mice and wild type controls. No significant differences were found between genotypes in either low (1 mg/kg) or high (30 mg/kg) EUK189 treated mice (Figure 1A). Next we asked if treatment with EUK189 within each genotype could have an effect on total tau levels. Interestingly, in wild type mice, there was a statistically significant drop in total tau (15%), as a result of increasing the concentration of EUK189 from 1 mg/kg to 30 mg/kg. In sod2 null mice, the same trend was observed; increasing the dosage of EUK189 from 1 mg/kg to 30 mg/kg significantly decreased the total load of tau by 45%.
###end p 40
###begin p 41
###xml 247 254 247 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 414 423 414 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1A</xref>
###xml 562 566 562 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 580 588 580 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1</xref>
###xml 574 578 <span type="species:ncbi:10090">mice</span>
To determine whether lack of mitochondrial sod2 could alter the phosphorylation status of specific tau residues (Ser-396, Ser-404, Ser-214, Thr-231, and Thr-205), we normalized the amount of total tau per animal through a regression analysis (see methods). Thus, we examined the level of phosphorylated tau at each of these residues without being confounded by the differential loads of tau seen between groups in Figure 1A. Treatment with EUK189 has no effect on phospho-tau epitopes in wild type controls, however EUK189 normalized phospho-tau epitopes in the sod2 mutant mice (Figure 1).
###end p 41
###begin p 42
###xml 0 9 0 9 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1B</xref>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 190 191 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 363 372 363 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1B</xref>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 184 188 <span type="species:ncbi:10090">mice</span>
Figure 1B shows that in the low dose treated sod2 null mice, there is a most prominent 7-fold increase in the hyperphosphorylation of tau at Thr-205 in sod2 null compared to wild type mice (p<0.001). There is also a trend for reduced phosphorylation of Thr-205 due to a higher dose of antioxidant treatment, although this does not reach statistical significance (Figure 1B).
###end p 42
###begin p 43
###xml 0 9 0 9 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1C</xref>
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 130 131 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 431 440 431 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1D</xref>
###xml 442 443 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 576 577 576 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 670 674 670 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 686 687 686 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 803 812 803 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1E</xref>
###xml 815 824 815 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1F</xref>
###xml 931 935 931 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 680 684 <span type="species:ncbi:10090">mice</span>
Figure 1C shows that lack of sod2 causes a more than 2-fold significant increase in the level of hyperphosphorylation of Ser-396 (p<0.001) over treatment-matched controls, and that increasing the dose of antioxidant significantly attenuates the level of hyperphosphorylation (p = 0.02). Similarly, for Ser-404, mitochondrial oxidative stress also increases the level of hyperphosphorylation of tau to 3-fold over treated controls (Figure 1D, p<0.001), while increasing the dosage of antioxidant to reduce oxidative stress rescues the hyperphosphorylation to wild-type levels (p<0.04). Ser-214 is the only phospho-tau epitope that was hypo-phosphorylated in the low dose sod2 null mice (p<0.001), with increased dose of antioxidant again normalizing the level of hypophosphorylation to wild-type levels (Figure 1E). Figure 1F shows an increase in the phosphorylation of Thr-231 (1.3 fold, p = 0.004) in the low-dose EUK-189 treated sod2 null animals, which is correspondingly rescued with high-dose EUK-189 antioxidant treatment (p = 0.004). Finally we asked if there were any sex specific effects with regard to differential phospho-tau loads between treatment groups, and there were no significant trends detected (data not shown).
###end p 43
###begin p 44
###xml 111 115 111 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 321 325 321 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 591 598 591 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 1029 1037 1029 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1</xref>
###xml 1647 1651 1647 1651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Augustinack1">[32]</xref>
###xml 1653 1660 1653 1660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000536-t001">Table 1</xref>
###xml 1748 1752 1748 1752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 361 365 <span type="species:ncbi:10090">mice</span>
###xml 1758 1762 <span type="species:ncbi:10090">mice</span>
In order to validate our initial observations of hyperphosphorylation of tau at residues associated with AD in sod2 null mice, we employed mass-spectrometry techniques as an alternate approach. To maximize the likelihood of detecting multiple sites of phosphorylation of tau, we immunoprecipitated total tau protein from sod2 null (treated with 1 mg/kg EUK189) mice using the Tau-5 monoclonal antibody, which detects both phosphorylated and non-phosphorylated forms of tau (Biosource). After releasing tau from the antibody, the protein was reduced, alkylated and digested with trypsin (see methods). Peptides were analyzed by MALDI TOF MS for peptide mass fingerprint analysis, then nano-HPLC-ESI-MS/MS. To determine site(s) of phosphorylation within tau protein the ESI-MS/MS spectra were searched by Mascot, and spectra shown to contain phosphorylated peptides were verified by manual inspection. Our mass spectrometric results corresponded with the positive phospho-antibody probing of tau for phosphorylation sites shown in Figure 1, such as phospho Ser-404, phospho Thr-231, and phospho Ser-396 (as determined by ESI-MS/MS and ESI-MS). The tryptic peptides covering phosphorylation site phospho Thr-205 clearly showed mono- and diphosphorylation events, but due to the complex assembly of potential serine and threonine residues the mass spectrometric studies could not provide unambiguous assignment of Thr-205 as the phosphorylation site. Additional data seen in our mass-spec data provided clear evidence for the site of phosphorylation of phospho Thr-181 and phospho Ser-159, two well-characterized sites of phosphorylation of tau in AD [32]. Table 1 shows the range of sites identified by mass spectrometry in brain tissue isolated from sod2 null mice.
###end p 44
###begin p 45
###xml 142 146 142 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 261 268 261 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
###xml 403 407 403 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Bancroft1">[36]</xref>
###xml 577 581 577 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 587 591 <span type="species:ncbi:10090">mice</span>
We next investigated whether pathological sequelae associated with hyperphosphorylation of tau in AD were also present in brain sections from sod2 null mice. We used a modified Gallyas stain to detect possible neurofibrillary tangles (NFTs) in tissue sections (methods). We also used Schiff staining to determine if any other pathology related to AD, such as insoluble amyloid plaques were also present [36]. We were unable to identify any pathology relating to NFTs or aberrant amyloid metabolism using either of these methods in sections throughout the brain from 3-week-old sod2 null mice on either low or high dose EUK189 (data not shown).
###end p 45
###begin title 46
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Mitochondrial oxidative stress increases phosphorylation of tau in Tg2576:sod2 mice
###end title 46
###begin p 47
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 363 367 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 547 551 547 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 553 557 553 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 778 782 778 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Hsiao1">[20]</xref>
###xml 1401 1405 1401 1405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 1438 1446 1438 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1</xref>
###xml 316 321 <span type="species:ncbi:10090">mouse</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 368 372 <span type="species:ncbi:10090">mice</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 467 471 <span type="species:ncbi:10090">mice</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 1411 1415 <span type="species:ncbi:10090">mice</span>
Having determined that mitochondrial oxidative stress causes hyperphosphorylation of tau, and that this can be ameliorated by antioxidant treatment, we next asked if there might be a synergistic interplay between aberrant amyloid metabolism and mitochondrial oxidative stress. Therefore, we crossed the Tg2576 (APP) mouse to hemizygous sod2 mice to create Tg2576:sod2 mice as described above. These double mutant mice are on an identical genetic background to Tg2576 mice. Therefore we aged four female genetically distinct groups (Tg2576, Tg2576:sod2, sod2+/-, and wild-type controls) on the same genetic background as the Tg2576 mice (F1 C57BL/6J: SJL hybrids), to approximately 16 months of age (when brain amyloid pathology is uniformly well-established in the Tg2576 model [20]) in order to investigate the effects of increased mitochondrial oxidative stress on amyloid and potential tau pathology. No difference in survival between the 4 groups was observed up to this age. The animals were sacrificed and the brains harvested, with half the brain being fixed and paraffin embedded for histological studies, while cortex from the other half was snap frozen for biochemical studies. Protein was extracted and equivalent amounts of protein from the 4 genetic groups were evaluated for levels of phospho Ser-396, a widely used epitope for detecting NFTs in AD, and readily induced in the brains of sod2 null mice compared to controls (Figure 1).
###end p 47
###begin p 48
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 163 167 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 177 180 177 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-VanRemmen1">[9]</xref>
###xml 206 210 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Opazo1">[19]</xref>
###xml 356 357 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 375 379 372 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 409 413 406 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 424 432 421 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g002">Figure 2</xref>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Levels of phospho Ser-396 in sod2+/- and Tg2576 mice were not significantly different from WT mice, indicating that oxidative stress induced by either loss of 50% sod2 activity [9] or cerebral beta-amyloid [19], was insufficient to impact levels of Ser-396 phosphorylation. However, we detected a significant 45% increase in the levels of phospho Ser-396 (p<0.003) in Tg2576:sod2 over the levels in Tg2576 or sod2+/- alone (Figure 2). This is consistent with synergy between amyloid load and increased mitochondrial oxidative stress in the hyperphosphorylation of tau.
###end p 48
###begin p 49
###xml 101 109 101 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g002">Figure 2</xref>
###xml 174 178 174 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 248 256 248 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g003">Figure 3</xref>
###xml 331 335 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Dewachter1">[37]</xref>
###xml 435 444 435 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g003">Figure 3B</xref>
###xml 504 508 504 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 184 188 <span type="species:ncbi:10090">mice</span>
###xml 509 513 <span type="species:ncbi:10090">mice</span>
Sections from fixed hemispheres of the same animals where Ser-396 phospho-tau levels were assayed in Figure 2 were stained for phospho Ser-396. In contrast to non-transgenic sod2 null mice, we detected dystrophic neurites positive for phospho tau (Figure 3), in a pattern previously reported to be associated with plaque pathology [37]. Absorption with the peptide specific for the phospho Ser-396 epitope abolished detectable signal (Figure 3B.). Comparison of IHC for Ser-396 between Tg2576 and Tg2576:sod2 mice (n = 3 each) revealed no qualitative or quantitative differences between the groups at the immunohistochemical level for hyperphosphorylated tau and no neurofibrillary tangles.
###end p 49
###begin title 50
###xml 62 66 <span type="species:ncbi:10090">mice</span>
Oxidative stress modulation is linked to Ass levels in Tg2576 mice
###end title 50
###begin p 51
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 101 116 <span type="species:ncbi:10090">transgenic mice</span>
We next investigated the effect of sod2 deficiency and Euk189 treatment upon brain Ass burden in APP transgenic mice.
###end p 51
###begin p 52
###xml 220 224 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 258 266 256 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g004">Figure 4</xref>
###xml 293 297 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 499 507 497 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g004">Figure 4</xref>
###xml 545 549 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 751 755 747 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 909 913 903 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 864 868 <span type="species:ncbi:10090">mice</span>
We used two different methods to test this hypothesis; we evaluated Ass plaque load by immunohistochemistry and also assessed Ass protein by ELISA in each of the different treatment groups (Tg2576+EUK189, Tg2576, Tg2576:sod2). The immunohistochemistry data (Figure 4) indicate that the Tg2576:sod2 animals have a 32% and a 29% increase in plaque burden as compared to Tg2576+EUK189 and Tg2576 animals respectively, which does not reach statistical significance (p = 0.18, p = 0.22). The ELISA data (Figure 4) demonstrates that Tg2576 and Tg2576:sod2 animals have a 73% (p = 0.01) and 52% (p = 0.3) increase in total Ass1-40 and a 172% (p = 0.04) and 265% (p = 0.02) increase in total Ass1-42 respectively, as compared to Tg2576+EUK189 animals. Tg2576:sod2 animals also show a 12% decrease in total Ass1-40 and a 34% increase in total Ass1-42 as compared to Tg2576 mice. These findings indicate that while the sod2 mutant allele did not have a discernable effect on total Ass levels, the antioxidant treatment did drop Ass levels significantly.
###end p 52
###begin p 53
###xml 129 137 128 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g005">Figure 5</xref>
###xml 143 147 142 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 179 183 178 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
The precursor to Ass, the amyloid precursor protein (APP), also showed significant modulation according to genotype. As shown in Figure 5, the sod2 mutation present in the Tg2576:sod2 animals resulted in a significant elevation (87%, p = 0.002) in total APP levels as compared to the Tg2576 background strain and a 47% (p = 0.02) increase compared to Tg2576 mice treated with EUK189.
###end p 53
###begin title 54
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Decreased metal content in Tg2576:sod2 mice
###end title 54
###begin p 55
###xml 50 54 50 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Bellingham1">[38]</xref>
###xml 56 60 56 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Maynard2">[39]</xref>
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Bayer1">[40]</xref>
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Phinney1">[41]</xref>
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
Because APP overexpression lowers cellular copper [38], [39] and decreased copper levels exacerbates amyloid pathology [40], [41], we investigated whether the synergistic interplay between sod2 ablation and Alzheimer pathology in Tg2576 transgenics is reflected by lowered brain metal levels.
###end p 55
###begin p 56
###xml 12 20 12 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g006">Figure 6</xref>
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 362 366 362 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 792 796 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 412 416 <span type="species:ncbi:10090">mice</span>
###xml 504 508 <span type="species:ncbi:10090">mice</span>
###xml 842 846 <span type="species:ncbi:10090">mice</span>
###xml 1002 1006 <span type="species:ncbi:10090">mice</span>
As shown in Figure 6, there is a decrease in copper levels in both the supernatant (25%, p = 0.01) and pellet (16%, p = 0.02) brain fractions of Tg2576:sod2 animals as compared to the Tg2576 background strain. Similarly, there is a significant decrease in manganese levels in both the pellet (23%, p = 0.01) and supernatant (35%, p = 0.0002) fractions of Tg2576:sod2 animals as compared to the background Tg2576 mice. There is also a significant increase in manganese levels in the EUK189 treated Tg2576 mice, as compared to the Tg2576 background strain, in both the pellet (113%, p = 0.002) and supernatant (91%, p = 0.0002) fractions. Similar trends are also shown for zinc, which shows a significant decrease in pellet (21%, p = 0.001) and supernatant (18%, p = 0.02) levels in the Tg2576:sod2 animals as compared to the background Tg2576 mice. We also found a significant increase in supernatant zinc levels (12%, p = 0.05) in the EUK189-treated Tg2576 animals as compared to the background Tg2576 mice.
###end p 56
###begin p 57
###xml 33 37 33 37 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Bellingham1">[38]</xref>
###xml 38 42 38 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Phinney1">[41]</xref>
###xml 258 266 258 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g007">Figure 7</xref>
###xml 355 359 355 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 376 387 376 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g006">Figure 6A&amp;B</xref>
###xml 285 300 <span type="species:ncbi:10090">transgenic mice</span>
Consistent with previous reports [38]-[41] and with an interaction of copper in our experimental system, we found that there is a significant inverse correlation between brain APP levels and both pellet (p = 0.0005) and supernatant (p = 0.02) copper levels (Figure 7) in the untreated transgenic mice. This implies that the decreased Cu levels in the APP:sod2 double mutants (Figure 6A&B) are caused by elevated APP expression.
###end p 57
###begin p 58
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
There was a marked decrease in the levels of Mn in both pellet and supernatant fractions of the Tg2576:sod2 mice compared to the control Tg2576 mice. SOD2 is a homotetramer requiring Mn for its catalytic activity. Our observations of a 23-35% decrease in Mn in both the pellet and supernatant fractions from the brains of Tg2576:sod2 mice compared to controls is consistent with the loss of SOD2. We also observed a 91-113% increase in the levels of Mn in the brains of mice treated with EUK189, which is a Mn-containing catalytic antioxidant. This is consistent with EUK189 or its bound Mn accumulating within the brain.
###end p 58
###begin title 59
Discussion
###end title 59
###begin p 60
###xml 201 205 201 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Barnham1">[15]</xref>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 595 598 595 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov1">[2]</xref>
###xml 649 653 649 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 934 938 934 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Hinerfeld1">[12]</xref>
###xml 1094 1097 1094 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Melov1">[2]</xref>
###xml 1099 1103 1099 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Hinerfeld1">[12]</xref>
###xml 1186 1190 1186 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 1247 1255 1247 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1</xref>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 659 663 <span type="species:ncbi:10090">mice</span>
###xml 1194 1198 <span type="species:ncbi:10090">mice</span>
Mitochondria are the chief source of ROS within the cell, and age-related oxidative damage in the brain has been associated with neurodegenerative diseases such as Alzheimer's and Parkinson's diseases [15]. We tested the hypothesis that mitochondrial oxidative stress could contribute to the two pathological hallmarks of AD, amyloid burden and hyperphosphorylation of tau. We initially evaluated the brains of 3-week old sod2 null animals treated with low and high doses of the catalytic antioxidant, EUK-189. These mice would die within the first week of life unless treated with antioxidants [2]. We previously developed the paradigm of treating sod2 null mice with differential doses of catalytic antioxidants, whereby at a low dose of treatment (1 mg/kg of catalytic antioxidant), the peripheral phenotypes are rescued and lifespan is extended, but a severe spongiform pathology with neurodegeneration develops by 3-weeks-of-age [12]. At high doses of catalytic antioxidant (30 mg/kg), the spongiform pathology is completely prevented, and the accompanying neurodegeneration is attenuated [2], [12]. Thus, we could compare the changes in amyloid/tau in the brains of wild-type and sod2-/- mice treated with low and high doses of antioxidant (Figure 1) in order to test the hypothesis that oxidative stress from mitochondrial dysfunction promotes AD-like pathology.
###end p 60
###begin p 61
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 236 240 234 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Bush1">[42]</xref>
###xml 393 401 391 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1</xref>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 116 121 <span type="species:ncbi:10090">mouse</span>
###xml 174 179 <span type="species:ncbi:10090">mouse</span>
We did not find evidence of increased amyloid burden in sod2 nullizygous neonatal mice, possibly because endogenous mouse Ass has three amino acid substitutions that prevent mouse Ass from being precipitated by synaptic copper and zinc [42]. However, we did find a striking increase in the levels of hyperphosphorylated tau at 3 weeks of age, which responded to catalytic antioxidant therapy (Figure 1).
###end p 61
###begin p 62
###xml 153 160 153 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000536-t001">Table 1</xref>
###xml 716 720 716 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Galas1">[43]</xref>
###xml 948 955 948 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000536-t001">table 1</xref>
###xml 1078 1082 1078 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Augustinack1">[32]</xref>
###xml 1113 1117 1113 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 1289 1297 1289 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1</xref>
###xml 712 716 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
We observed a significant increase in the level of hyperphosphorylation in 4 out of 5 specific residues evaluated compared to control wild-type animals (Table 1). We did observe one residue (Ser-214) that was hypophosphorylated in response to mitochondrial oxidative stress. The phosphorylation status of various residues in tau results from a complex interplay between the inhibition and activation of kinases and phosphatases specific for individual residues. A recent report shows that a peptidyl-prolyl cis/trans isomerase (Pin1) caused hypophosphorylation of Thr-231, Thr-212, Ser-396, and Ser-404 in response to an extracellular hydrogen peroxide stress in primary neuronal cultures isolated from neonatal rats[43]. Hence, extracellular oxidative stress can cause hypophosphorylation of specific residues in tau. In contrast, we show here that intracellular oxidative stress appears to cause hyperphosphorylation in most residues we studied (table 1). Each of these hyperphosphorylated residues has been previously associated with aggregated hyperphosphorylated tau in AD [32], and in the high-dose treated sod2 null animals, we observed a significant normalization of phosphorylation toward wild-type levels of phosphorylation in 3 out of 4 residues which were hyperphosphorylated (Figure 1). Thr-205 did not reach significance (although a trend consistent with the other three residues was apparent), possibly due to more noise in this particular group. Overall, we conclude that hyperphosphorylated tau which is caused by mitochondrial oxidative stress could be resolved with appropriate antioxidant therapy.
###end p 62
###begin p 63
###xml 116 120 116 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Esposito1">[26]</xref>
###xml 122 126 122 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Blass1">[44]</xref>
###xml 127 131 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Smith2">[46]</xref>
###xml 182 186 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Lustbader1">[47]</xref>
###xml 188 192 187 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Takuma1">[48]</xref>
###xml 216 220 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Crouch1">[49]</xref>
###xml 287 291 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Lustbader1">[47]</xref>
###xml 593 597 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Marcus1">[50]</xref>
###xml 780 784 779 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 833 836 832 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-VanRemmen1">[9]</xref>
###xml 838 842 837 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-VanRemmen2">[51]</xref>
###xml 844 848 843 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-VanRemmen3">[52]</xref>
###xml 945 949 944 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 979 987 978 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1</xref>
###xml 1084 1088 1083 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Augustinack1">[32]</xref>
###xml 1352 1356 1351 1355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 1372 1380 1371 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g002">Figure 2</xref>
###xml 1630 1638 1629 1637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g004">Figure 4</xref>
###xml 1747 1757 1746 1756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">drosophila</italic>
###xml 1757 1761 1756 1760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-DiasSantagata1">[53]</xref>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 584 592 <span type="species:ncbi:9606">patients</span>
###xml 708 713 <span type="species:ncbi:10090">mouse</span>
###xml 749 754 <span type="species:ncbi:10090">mouse</span>
###xml 758 762 <span type="species:ncbi:10090">mice</span>
###xml 1121 1125 <span type="species:ncbi:10090">mice</span>
###xml 1337 1341 <span type="species:ncbi:10090">mice</span>
A number of prior studies have found associations between mitochondrial dysfunction and AD, and animal models of AD [26], [44]-[46]. Ass inhibits mitochondrial alcohol dehydrogenase [47], [48] and cytochrome oxidase [49] leading to increased mitochondrial oxidative stress and apoptosis [47]. A recent report also demonstrated a 9-11 fold increase in the expression of SOD2 by immunohistochemistry in the hippocampus of Alzheimer patients compared to controls, indicating a possible upregulation of antioxidant defenses in response to a pro-oxidant environment within the brain of AD patients [50]. To investigate the consequences of increased mitochondrial oxidative stress in the context of an established mouse model of AD, we crossed the Tg2576 mouse to mice heterozygous for sod2, a model of mild mitochondrial oxidative stress [9], [51], [52]. Concomitant with our observations of increased hyperphosphorylation of tau as a consequence of sod2 knockout as described above (Figure 1), we investigated the levels of Ser-396 phospho-tau, which is characteristically elevated in AD [32], in the brains of double mutant mice compared to controls. We found a robust increase in the levels of phospho Ser-396 as a consequence of increased mitochondrial oxidative stress, above and beyond that seen in either parental control line, Tg2576 mice alone, or sod2 heterozygotes (Figure 2). This implies that there is a synergistic interplay between mitochondrial dysfunction and amyloid burden that leads to hyperphosphorylation of tau. We also found a relationship between the level of oxidative stress and the level of amyloid burden (Figure 4). A recent report also found evidence of oxidative stress being linked to tau-mediated neurodegeneration in drosophila[53].
###end p 63
###begin p 64
###xml 53 62 53 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g004">Figure 4A</xref>
###xml 75 84 74 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g004">Figure 4C</xref>
###xml 101 105 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 268 272 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 316 320 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Li2">[27]</xref>
###xml 505 509 504 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 552 556 551 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Esposito1">[26]</xref>
###xml 702 706 700 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 914 918 912 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Li3">[54]</xref>
###xml 958 962 956 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 967 971 965 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Esposito1">[26]</xref>
###xml 1135 1139 1133 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Esposito1">[26]</xref>
###xml 1141 1145 1139 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Li2">[27]</xref>
###xml 536 551 <span type="species:ncbi:10090">transgenic mice</span>
###xml 963 967 <span type="species:ncbi:10090">mice</span>
###xml 1094 1098 <span type="species:ncbi:10090">mice</span>
###xml 1286 1291 <span type="species:ncbi:10090">mouse</span>
The trends we observed, of increased amyloid burden (Figure 4A) and Ass42 (Figure 4C) as a result of sod2 heterozygosity, is consistent with a previous report where amyloid load was increased by approximately 2 fold compared to controls through genetic combination of sod2 heterozygotes with the Tg19959 model of AD [27]. However, a more recent report observed decreased plaque burden in the parenchyma, with increased vascular amyloid, gliosis and exaggerated neurocognitive deficits as a consequence of sod2 heterozygosity in J20 APP transgenic mice [26]. It is worth noting that Esposito et al., also found enhanced loss of microtubule-dependant protein 2 (MAP2) that was APP/Ass dependant in their sod2/APP model (which differs from the model we report here). MAP2 is involved in maintaining microtubule integrity like tau, and depletion of MAP2 is often observed in association with hypephosphorylation of tau[54]. Hence it is possible that the J20 APP/sod2 mice[26], may also be experiencing hyperphosphorylation of tau, given the reported apparent loss of MAP2 in in the brains of these mice. Collectively, these three studies ([26], [27], and the data we report here) confirm that the SOD2 allele impacts upon AD-like pathology, but clearly the effects vary according to the AD mouse model utilized. Our study is the first to describe an association between SOD2 knockout or antioxidant-modulated oxidative stress and tau phosphorylation, which has not been investigated previously.
###end p 64
###begin p 65
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Maynard2">[39]</xref>
###xml 170 174 170 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Phinney1">[41]</xref>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Cherny1">[55]</xref>
###xml 545 549 545 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 863 867 863 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Bayer1">[40]</xref>
###xml 869 873 869 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000536-Phinney1">[41]</xref>
###xml 977 981 977 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 80 95 <span type="species:ncbi:10090">transgenic mice</span>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
Previous studies have demonstrated that copper and iron levels in the brains of transgenic mice are lowered by expressing mutant APP or the carboxyl terminus of APP [39]-[41]. Consistent with metal deficiency fostering amyloid accumulation, we have previously found that amyloid clearance induced by clioquinol is associated with an elevation of cortical zinc and copper in the brains of Tg2576 mice [55]. Our current findings indicate that brain Cu, Zn, Fe, and Mn levels are all decreased as a consequence of genetic combination of Tg2576 and sod2 heterozygotes. While the significance of this finding is not clear, these metals all participate in essential cellular function. It is likely that the drop in energy that results from the mitochondrial damage leads to a loss of brain metals. Decreased intracellular copper levels may exacerbate amyloid pathology [40], [41] by a mechanism that is not yet clear. Therefore, the drop in brain copper levels induced by the Tg2576:sod2 double mutation may contribute to the increased amyloid burden in double mutants.
###end p 65
###begin p 66
###xml 179 187 179 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g008">Figure 8</xref>
###xml 272 277 <span type="species:ncbi:10090">mouse</span>
###xml 302 307 <span type="species:ncbi:10090">mouse</span>
###xml 396 401 <span type="species:ncbi:10090">mouse</span>
###xml 460 465 <span type="species:ncbi:10090">mouse</span>
###xml 634 639 <span type="species:ncbi:9606">human</span>
In summary, we have shown that mitochondrial oxidative stress per se causes hyperphosphorylation of tau, and that this can be prevented through appropriate antioxidant treatment (Figure 8). We have also demonstrated that the aggregate amyloid burden in a well established mouse model of AD (the Tg2576 mouse) is influenced by mitochondrial oxidative stress. This has implications for how we view mouse models of AD, in that to our knowledge, this is the first mouse model of AD that recapitulates two of the canonical hallmarks of AD pathology: plaques, and hyperphosphorylated tau, without resorting to overexpression of both mutant human proteins. Hyperphosphorylated tau is a component of neurofibrillary tangles, the formation of which is closely associated with the dementia process in AD. These findings encourage the use of ROS-scavenging antioxidants as being of potential therapeutic utility in AD.
###end p 66
###begin title 67
References
###end title 67
###begin article-title 68
###xml 124 130 <span type="species:ncbi:10090">murine</span>
Heterozygous deficiency of manganese superoxide dismutase results in severe lipid peroxidation and spontaneous apoptosis in murine myocardium in vivo.
###end article-title 68
###begin article-title 69
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics.
###end article-title 69
###begin article-title 70
###xml 34 38 <span type="species:ncbi:10090">mice</span>
A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase.
###end article-title 70
###begin article-title 71
Optic neuropathy induced by reductions in mitochondrial superoxide dismutase.
###end article-title 71
###begin article-title 72
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase.
###end article-title 72
###begin article-title 73
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Genetic modification of prenatal lethality and dilated cardiomyopathy in Mn superoxide dismutase mutant mice.
###end article-title 73
###begin article-title 74
###xml 59 65 <span type="species:ncbi:10090">murine</span>
Absence of mitochondrial superoxide dismutase results in a murine hemolytic anemia responsive to therapy with a catalytic antioxidant.
###end article-title 74
###begin article-title 75
SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness.
###end article-title 75
###begin article-title 76
Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging.
###end article-title 76
###begin article-title 77
###xml 65 70 <span type="species:ncbi:10090">mouse</span>
Mitochondrial oxidative stress causes chromosomal instability of mouse embryonic fibroblasts.
###end article-title 77
###begin article-title 78
###xml 55 59 <span type="species:ncbi:10090">mice</span>
Mitochondrial disease in superoxide dismutase 2 mutant mice.
###end article-title 78
###begin article-title 79
###xml 185 189 <span type="species:ncbi:10090">mice</span>
Endogenous mitochondrial oxidative stress: neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice.
###end article-title 79
###begin article-title 80
A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties.
###end article-title 80
###begin article-title 81
Pharmacogenomic profiling of an oxidative stress-mediated spongiform encephalopathy.
###end article-title 81
###begin article-title 82
Neurodegenerative diseases and oxidative stress.
###end article-title 82
###begin article-title 83
Tau pathology in Alzheimer disease and other tauopathies.
###end article-title 83
###begin article-title 84
Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology.
###end article-title 84
###begin article-title 85
The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction.
###end article-title 85
###begin article-title 86
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).
###end article-title 86
###begin article-title 87
###xml 69 84 <span type="species:ncbi:10090">transgenic mice</span>
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice [see comments].
###end article-title 87
###begin article-title 88
###xml 118 133 <span type="species:ncbi:10090">transgenic mice</span>
Intraneuronal Abeta accumulation precedes plaque formation in beta- amyloid precursor protein and presenilin-1 double-transgenic mice.
###end article-title 88
###begin article-title 89
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse models of Alzheimer's disease: a quest for plaques and tangles.
###end article-title 89
###begin article-title 90
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.
###end article-title 90
###begin article-title 91
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease.
###end article-title 91
###begin article-title 92
###xml 39 44 <span type="species:ncbi:10090">mouse</span>
Tau suppression in a neurodegenerative mouse model improves memory function.
###end article-title 92
###begin article-title 93
###xml 144 149 <span type="species:ncbi:9606">human</span>
###xml 176 191 <span type="species:ncbi:10090">transgenic mice</span>
Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice.
###end article-title 93
###begin article-title 94
###xml 76 80 <span type="species:ncbi:10090">mice</span>
Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice.
###end article-title 94
###begin article-title 95
###xml 20 35 <span type="species:ncbi:10090">transgenic mice</span>
Single and multiple transgenic mice as models for Alzheimer's disease.
###end article-title 95
###begin article-title 96
###xml 40 55 <span type="species:ncbi:10090">transgenic mice</span>
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes.
###end article-title 96
###begin article-title 97
###xml 75 90 <span type="species:ncbi:10090">transgenic mice</span>
Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice.
###end article-title 97
###begin article-title 98
Gallyas-Schiff stain for senile plaques.
###end article-title 98
###begin article-title 99
Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.
###end article-title 99
###begin article-title 100
A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity.
###end article-title 100
###begin article-title 101
Probability-based protein identification by searching sequence databases using mass spectrometry data.
###end article-title 101
###begin article-title 102
###xml 89 93 <span type="species:ncbi:10090">mice</span>
Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology.
###end article-title 102
###begin article-title 103
###xml 32 47 <span type="species:ncbi:10090">transgenic mice</span>
###xml 134 138 <span type="species:ncbi:10090">mice</span>
Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice.
###end article-title 103
###begin article-title 104
###xml 124 129 <span type="species:ncbi:10090">mouse</span>
Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts.
###end article-title 104
###begin article-title 105
Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron.
###end article-title 105
###begin article-title 106
###xml 106 121 <span type="species:ncbi:10090">transgenic mice</span>
Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice.
###end article-title 106
###begin article-title 107
In vivo reduction of amyloid-beta by a mutant copper transporter.
###end article-title 107
###begin article-title 108
Rapid induction of Alzheimer A beta amyloid formation by zinc.
###end article-title 108
###begin article-title 109
The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease.
###end article-title 109
###begin article-title 110
Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia?
###end article-title 110
###begin article-title 111
###xml 37 52 <span type="species:ncbi:10090">transgenic mice</span>
Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress.
###end article-title 111
###begin article-title 112
Mitochondrial Abnormalities: A Primary Basis for Oxidative Damage in Alzheimer's Disease.
###end article-title 112
###begin article-title 113
ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease.
###end article-title 113
###begin article-title 114
ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction.
###end article-title 114
###begin article-title 115
Therapeutic treatments for Alzheimer's disease based on metal bioavailability.
###end article-title 115
###begin article-title 116
Differential neuronal expression of manganese superoxide dismutase in Alzheimer's disease.
###end article-title 116
###begin article-title 117
###xml 103 108 <span type="species:ncbi:10090">mouse</span>
Characterization of the antioxidant status of the heterozygous manganese superoxide dismutase knockout mouse.
###end article-title 117
###begin article-title 118
###xml 9 13 <span type="species:ncbi:10090">mice</span>
Knockout mice heterozygous for Sod2 show alterations in cardiac mitochondrial function and apoptosis.
###end article-title 118
###begin article-title 119
###xml 59 69 <span type="species:ncbi:7227">Drosophila</span>
Oxidative stress mediates tau-induced neurodegeneration in Drosophila.
###end article-title 119
###begin article-title 120
Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau.
###end article-title 120
###begin article-title 121
###xml 117 132 <span type="species:ncbi:10090">transgenic mice</span>
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.
###end article-title 121
###begin title 122
Figures and Tables
###end title 122
###begin title 123
Mitochondrial oxidative stress causes hyperphosphorylation of tau.
###end title 123
###begin p 124
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
Western blots of cortical extracts from sod2 null mice treated with 1 mg/kg (n = 8) of the catalytic antioxidant EUK189 or 30 mg/kg (n = 7) of EUK189 (white bars), or wild-type mice (n = 6, 1 mg/kg; n = 7, 30 mg/kg) treated comparably (black bars), were probed with the following antiphospho-tau antibodies; Thr 205, Ser 396, Ser 404, Ser 214, and Thr-231. Quantitation of chemiluminesence was carried out in the linear range of detection for each of these antibodies, using a regression model to adjust for the total amount of tau (results). P values for comparisons between each of the residues of phospho-tau were derived from the regression model, after correcting for the total amount of tau per group.
###end p 124
###begin title 125
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Mitochondrial oxidative stress results in a synergistic increase in the levels of phospho-tau in Tg2576 mice.
###end title 125
###begin p 126
###xml 196 200 182 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 231 235 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 395 399 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
Data show the mean+/-SD levels of Ser-396 phospho-tau assayed by Western blot of cortical extracts from mice of approximately500 days of age from each of the following genotypes: wild-type n = 4, sod2+/-n = 4, Tg2576 n = 8, Tg2576:sod2 n = 9 (all matched for genetic background). A non parametric t test was carried out between genotypes, and a significant increase in phospho tau in the Tg2576:sod2 mice was observed, compared to controls.
###end p 126
###begin title 127
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Immunohistochemical identification of phospho-tau positive dystrophic neurites in Tg2576:sod2 mice.
###end title 127
###begin p 128
###xml 163 167 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
(a) Immunohistochemistry for anti Ser-396 was carried out as described in the text, and positivity was observed surrounding senile plaques in the brains of Tg2576:sod2 mice. (b) In order to ensure specificity, we also tested the effects of preadsorbing the Ser-396 antibody with the peptide the antibody was raised against. This abolished the staining seen around the plaques.
###end p 128
###begin title 129
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
Exacerbation of amyloid load by genetic combination of lack of sod2 and overexpression of APP.
###end title 129
###begin p 130
###xml 223 227 209 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 402 406 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 475 480 <span type="species:ncbi:10090">mouse</span>
(a) Immunohistochemistry quantitation (area occupied by Ass/mm2) did not demonstrate any significant alterations in total Ass plaque burden, although there is an approximately30% increase (p = 0.2) in plaques in the Tg2576:sod2 animals as compared to other groups. (b) ELISA quantitation demonstrates that EUK189 treatment significantly modulates Ass levels. Furthermore, genetically combining lack of sod2 with overexpression of mutant APP elevates Ass levels in the Tg2576 mouse. The data indicate mean+/-SD.
###end p 130
###begin title 131
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
APP levels are elevated by genetic combination of sod2 with Tg2576 mice.
###end title 131
###begin p 132
###xml 160 164 <span type="species:ncbi:10090">mice</span>
The data indicate mean+/-SD APP levels in brain assayed by western blot. As compared to the baseline Tg2576 levels, APP protein was marginally higher in Tg2576 mice treated with EUK189 (29% increased, p = 0.2), but markedly elevated by the presence of the sod2 mutation (88% increased, p = 0.002).
###end p 132
###begin title 133
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
Metal levels are lowered by genetic combination of lack of sod2 and overexpression of APP.
###end title 133
###begin p 134
###xml 312 316 310 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
Data indicate mean+/-SD brain metal levels in the various genotypes, as indicated. This revealed a significant decrease in insoluble (16%) (A) and soluble (25%) (B) Copper levels, insoluble (23%) (C) and soluble (35%) (D) Manganese levels, and insoluble (21%) (E) and soluble (18%) (F) Zinc levels in the Tg2576:sod2 animals compared to the Tg2576 background strain. EUK189 treatment increased soluble (91%) and insoluble (113%) Manganese and soluble (12%) Zinc levels in the Tg2576 animals.
###end p 134
###begin title 135
APP vs. copper correlation.
###end title 135
###begin p 136
###xml 111 115 111 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
Levels of APP and Copper in the soluble and pellet phases of brain homogenate from untreated Tg2576 and Tg2576:sod2 crossed mice (pooled) were compared graphically and found to correlate strongly (* p<0.02).
###end p 136
###begin title 137
Model of potential interactions between increasing Ass, decreased activity of SOD2, and a resultant increase in the hyperphosphorylation of tau.
###end title 137
###begin p 138
As levels of Ass increase with age, this causes a concomitant decrease in the activity of SOD2, which in turn leads to increased aggregation of Ass. The resulting pro-oxidant state of the cell causes hyperphosphorylation of tau.
###end p 138
###begin title 139
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
Tau phosphorylation sites identified in sod2 null mouse brain tissue
###end title 139
###begin p 140
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</bold>
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sod2</italic>
###xml 107 115 107 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000536-g001">Figure 1</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
a: Percent changes of listed residue in sod2 null mice relative to sod2wild-types (normalized to 100%, see Figure 1), both treated with EUK189 at 1 mg/kg quantitated by Western blotting with monoclonal antibodies for the indicated tau residues, NS- not significant, ND - not done.
###end p 140
###begin p 141
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</bold>
b: identifications were positive (+) if a MS/MS spectrum could be unambiguously interpreted to identify a unique phosphorylation site. In three cases (+/-) assignments were based on MS or MS/MS data and alternative sites were possible.
###end p 141
###begin p 142
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</bold>
c: several matching phospho peptides observed by ESI-MS (i.e., peptides: mono-/di-phosph. S195-R209 and mono-/di-phosph. S181-R209);
###end p 142
###begin p 143
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</bold>
d: Phosphorylate site possibly on Ser-404, Thr-403 or Ser-400;
###end p 143
###begin p 144
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</bold>
e: peptide observed with 1P and 2P groups;
###end p 144
###begin p 145
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</bold>
###xml 128 129 128 129 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</underline>
###xml 130 131 130 131 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</underline>
###xml 136 137 136 137 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</underline>
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
###xml 112 117 <span type="species:ncbi:9606">human</span>
f: differences in peptide sequence (human vs. mouse) likely accounting for negative antibody result (homologous human peptide: TPPAPKTPPSSGEPPK);
###end p 145
###begin p 146
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</bold>
g: no antibody available for Ser-159.
###end p 146
###begin p 147
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 147
###begin p 148
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by National Institutes of Health grants AG18679 and PO1 AG25901 (S.M), AG12686 (A.I.B.), and a grant from the American Health Assistance Foundation (A.I.B.). It was also supported by an award from the Institute for the Study of Aging and an Ellison Medical Foundation award (S.M); the Australian Research Council Federation Fellowship (A.I.B.); the National Health and Medical Research Council Howard Florey Centenary Research Fellowship (P.A). We would like to thank Nicole Nagulko and Lawreen Asuncion for excellent animal work, and Sue Doctrow for helpful comments.
###end p 148

